MUMBAI, 9 JULY, 2025 (GPN): Anthem Biosciences Limited Rs. 3,395 crore IPO is set to open on Monday 14 July 2025 and will close on Wednesday 16 July 2025, with the anchor book slated to open on Friday 11 July 2025. Anthem Biosciences IPO price band has been fixed at Rs. 540 to Rs. 570 per share of face value of Rs. 2 each equity share.
The issue is entirely an offer for sale of 5.96 crore shares, meaning no proceeds will go to the company, but the shareholders are offloading their stake.
In Anthem Biosciences IPO, 50% of the offer is reserved for qualified institutional buyers (QIB), 15% for non-institutional investors (NII) and 35% for retail investors. Equity shares aggregating up to Rs. 8.25 crore have been reserved for eligible employees.
Investors can apply for Anthem Biosciences IPO in the lots of 26 shares, requiring a minimum investment of Rs.14,820 by the retail investors.
Anthem Biosciences is an innovation-driven, technology-focused Contract Research, Development, and Manufacturing Organization (CRDMO) with fully integrated operations across drug discovery, development, and commercial manufacturing.
The company also specialises in the production and sale of complex, fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
Anthem operates two manufacturing facilities in Karnataka, India—Unit I in Bommassandra and Unit II in Harohalli. As of March 31, 2025, the facilities have a combined annual capacity of 270 kL for custom synthesis and 142 kL for fermentation processes.
Listed peers of Anthem Biosciences include Sai Life Sciences Ltd, Syngene International, Suven Life Sciences, and Divi’s Laboratories.
JM Financial Ltd, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) Pvt Ltd are the book-running lead managers for the issue while KFin Technologies is the registrar.
Following the closure of the public offer, Anthem Biosciences IPO’s allotment will be finalised the next day on July 17, with initiation of refund and credit of shares expected on July 18. The tentative listing date for Anthem Biosciences shares is July 21. The shares will list on both BSE and National Stock Exchange (NSE).
About Anthem Biosciences Ltd.
In discussion with GPN news agency at the Anthem Biosciences Limited IPO launch, Company Spokespersons: 1)Ajay Bhardwaj, Chairman, Managing Director & CEO, Anthem Biosciences Limited 2) Gawir Baig, Chief Financial Officer, Anthem Biosciences Limited
3) Ganesh Sambasivam, Chief Scientific Officer, Anthem Biosciences Limited
4) K Ravindra Chandrappa, Chief Operating Officer, Anthem Biosciences Limited 5) Ishaan Bhardwaj, Vice President & Promoter, Anthem Biosciences Limited, said,
“We are an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”) with fully integrated operations spanning across drug discovery, development and manufacturing. We are one of the few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing, according to the F&S Report.
As of March 31, 2025, we had more than 550 customers across both our CRDMO and specialty ingredients businesses, respectively, spread over more than 44 countries including the United States, European countries and Japan, many of whom we have a long-standing relationship with. According to the F&S Report, we have the most number of customers as compared to our assessed Indian peers as of March 2025. In our CRDMO business, as of March 31, 2025, we have served over 150 customers, ranging from small pharmaceutical and emerging biotech companies to mid-scale and large pharmaceutical companies. We also serve 3 large pharmaceutical companies for whom we manufactured 5 of our top 6 commercialized molecules by revenue in Fiscal 2025 (including after acquisitions or consolidations):
As a one-stop service provider, we serve a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. We are one of the youngest Indian CRDMO companies and the fastest Indian CRDMO among the assessed peers to achieve a milestone of Rs.10,000 million of revenue within 14 years of operations, reaching this milestone in Fiscal 2021, according to the F&S Report. We also recorded the highest revenue growth in Fiscal 2024 to Fiscal 2025 as compared to our assessed peers in India and globally, according to the F&S Report.”
Be the first to comment on "Anthem Biosciences Limited Rs. 3,395 Crore IPO Opens On 14 July 2025 Price Band Set At Rs. 540 – 570 Per Share"